Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled...

Read more: Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

More Articles …

  1. America's Fastest Growing Company Joined Australia in Alleviating the IT Talent Shortfall
  2. Ian Schrager Relaunches His Transformative New Brand Public for A New Beginning for Both the Hotel and New York City
  3. Earlytrade Report: Govt support not enough for traumatised Melbourne businesses entering extended lockdown
  4. Wood Mackenzie announces inaugural Power & Renewables APAC Conference
  5. 2021 Nintex Solution Innovation Award Finalists Announced
  6. Poq Joins Forces with Gameloft for brands to Bring Mobile Gaming Experiences to Retail App Shoppers
  7. Rapyd Launches a Venture Arm to Propel Digital Commerce and Payment Innovation Globally
  8. Agoda Sustainable Travel Trends Survey Reveals People's Top Concerns about Tourism's Impact, and Measures to Make Travel More Sustainable
  9. Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia
  10. Independent Research Firm Cites Stibo Systems As A Leader In Product Information Management